2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease---Part II

Here are the 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease---Part II journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Gina guidelines 2024, cdc sti guidelines 2024, taiwan travel guide 2024, taiwan travel restrictions 2024, icd 10 cm guidelines 2024, 2024 guidelines for diabetes, travel to taiwan 2024, work in taiwan 2024, 2024 tip report taiwan, 2024 guidelines for perioperative practice.

2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease---Part II

For the primary prevention of atherosclerotic cardiovascular disease (ASCVD), the recommended treatment target for each modifiable risk factor is as follows: reducing body weight by 5-10%; blood pressure < 130/80 mmHg (systolic pressure < 120 mmHg in high-risk individuals); low-density lipoprotein cholesterol (LDL-C) < 100 mg/dL in high-risk individuals, LDL-C < 115 mg/dL in moderate-risk individuals, LDL-C < 130 mg/dL in low-risk individuals, and LDL-C < 160 mg/dL in those with a minimal; complete and persistent abstinence from cigarette smoking; hemoglobin A1C < 7.0%; fulfilling recommended amounts of the six food groups according to the Taiwan food guide; and moderate-intensity physical activity 150 min/wk or vigorous physical activity 75 min/wk. For the primary prevention of ASCVD by pharmacological treatment in individuals with modifiable risk factors/clinical conditions, statins are the first-line therapy for reducing LDL-C levels; some specific anti-diabetic drugs prov en to be effective in randomized controlled trials for the primary prevention of ASCVD are recommended in patients with type 2 diabetes mellitus; pharmacological treatment is recommended to assist in weight management for obese patients with a body mass index ≥ 30 kg/m2 (or 27 kg/m2 who also have at least one ASCVD risk factor or obesity-related comorbidity); an angiotensin-converting enzyme inhibitor, a glucagon-like peptide-1 receptor agonist, a sodium-dependent glucose cotransporter-2 inhibitor, and finerenone can be used in diabetic patients with chronic kidney disease for the primary prevention of ASCVD. Of note, healthcare providers are at full discretion in clinical practice, owing to the diversity of individuals and practice, and the availability of resources and facilities. © 2024, Republic of China Society of Cardiology. All rights reserved.

Authors : Chao T.-H.; Lin T.-H.; Cheng C.-I.; Wu Y.-W.; Ueng K.-C.; Wu Y.-J.; Lin W.-W.; Leu H.-B.; Cheng H.-M.; Huang C.-C.; Wu C.-C.; Lin C.-F.; Chang W.-T.; Pan W.-H.; Chen P.-R.; Ting K.-H.; Su C.-H.; Chu C.-S.; Chien K.-L.; Yen H.-W.; Wang Y.-C.; Su T.-C.; Liu P.-Y.; Chang H.-Y.; Chen P.-W.; Juang J.-M.J.; Lu Y.-W.; Lin P.-L.; Wang C.-P.; Ko Y.-S.; Chiang C.-E.; Hou C.J.-Y.; Wang T.-D.; Lin Y.-H.; Huang P.-H.; Chen W.-J.

Source : Republic of China Society of Cardiology